Headlands Research Acquires Clinvest Research
Headlands Researchhas announced the acquisition of Clinvest Research, an established site based in Springfield, Missouri. Founded in 1996, Clinvest Research has conducted over 600 trials for chronic diseases and conditions such as headache and migraine, arthritis and chronic pain, and diabetes, as well as weight loss.
By combining Clinvest Research’s expertise with the 11 other sites in the Headlands Research site network studying chronic conditions, Headlands Research is able to access a greater participant population for clinical trials conducted in the US and Canada.
Headlands Research also recently announced the launch of Headlands Research Detroit as well as the acquisition of Headlands Eastern Massachusetts and has plans to continue expanding its network throughout 2023.
Reference
Headlands Research Acquires Clinvest Research — the Clinical Research Site Network’s Third Addition of 2023. (2023, May 4). Business Wire.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
